Fmc-Inglewood in Inglewood, California - Dialysis Center

Fmc-Inglewood is a medicare approved dialysis facility center in Inglewood, California and it has 20 dialysis stations. It is located in Los Angeles county at 336 E. Hillcrest Avenue, Suite 100, Inglewood, CA, 90301. You can reach out to the office of Fmc-Inglewood at (310) 673-3656. This dialysis clinic is managed and/or owned by Fresenius Medical Care. Fmc-Inglewood has the following ownership type - Profit. It was first certified by medicare in June, 1999. The medicare id for this facility is 052846 and it accepts patients under medicare ESRD program.

Dialysis Center Profile

NameFmc-Inglewood
Location336 E. Hillcrest Avenue, Suite 100, Inglewood, California
No. of Dialysis Stations 20
Medicare ID052846
Managed ByFresenius Medical Care
Ownership TypeProfit
Late Shifts No

Contact Information


336 E. Hillcrest Avenue, Suite 100, Inglewood, California, 90301
(310) 673-3656

News Archive

Risk factors for head and neck cancer among WTC responders identified

A recent Rutgers study identified factors that may put people who responded to the 9/11 terrorist attacks at the World Trade Center at increased risk for cancers of the head and neck, such as oral cavity, oropharyngeal, and laryngeal cancers.

One-third of PsA patients not receiving adalimumab doses to achieve optimal clinical benefit

Data presented today at the European League Against Rheumatism Annual Congress showed that a significant number of patients with psoriatic arthritis (PsA) were not receiving doses of the tumour necrosis factor-alpha (TNFα) inhibitor adalimumab necessary to achieve optimal clinical benefit.

Zafgen presents safety, efficacy data from beloranib Phase 2 study at Obesity Week 2013

Zafgen, Inc., a leading biopharmaceutical company dedicated to addressing the unmet needs of severely obese patients, today announced final efficacy and safety data from its recently completed Phase 2 study of beloranib, a selective inhibitor of methionine aminopeptidase 2.

National veteran dataset will help dissect the relationship between mental illness and prostate cancer

There appears to be an unhealthy synergy between mental illness and prostate cancer, and researchers are working to dissect the relationship by first assembling the largest dataset ever of veterans with either condition or both.

Read more Medical News

› Verified 6 days ago


Map and Direction



NPI Associated with this Dialysis Facility:

Dialysis Facilities may have multiple NPI numbers. We have found possible NPI number/s associated with Fmc-Inglewood from NPPES records by matching pattern on the basis of name, address, phone number etc. Please use this information accordingly.

NPI Number1477503654
Organization NameFresenius Medical Care Of Inglewood
Doing Business AsBio-medical Applications Of California, Inc.
Address336 E Hillcrest Blvd Inglewood, California, 90301
Phone Number(310) 673-3656

News Archive

Risk factors for head and neck cancer among WTC responders identified

A recent Rutgers study identified factors that may put people who responded to the 9/11 terrorist attacks at the World Trade Center at increased risk for cancers of the head and neck, such as oral cavity, oropharyngeal, and laryngeal cancers.

One-third of PsA patients not receiving adalimumab doses to achieve optimal clinical benefit

Data presented today at the European League Against Rheumatism Annual Congress showed that a significant number of patients with psoriatic arthritis (PsA) were not receiving doses of the tumour necrosis factor-alpha (TNFα) inhibitor adalimumab necessary to achieve optimal clinical benefit.

Zafgen presents safety, efficacy data from beloranib Phase 2 study at Obesity Week 2013

Zafgen, Inc., a leading biopharmaceutical company dedicated to addressing the unmet needs of severely obese patients, today announced final efficacy and safety data from its recently completed Phase 2 study of beloranib, a selective inhibitor of methionine aminopeptidase 2.

National veteran dataset will help dissect the relationship between mental illness and prostate cancer

There appears to be an unhealthy synergy between mental illness and prostate cancer, and researchers are working to dissect the relationship by first assembling the largest dataset ever of veterans with either condition or both.

Read more Medical News

› Verified 6 days ago


Survey of Patient's Experiences

Nephrologists Performance Ratings

Experience MeasureProviderNational Avg.
Patients who reported that nephrologists always communicated and cared for them.69%67%
Patients who reported that nephrologists usually communicated and cared for them.11%15%
Patients who reported that nephrologists sometimes or never communicated and cared for them.20%18%
Patients who gave their nephrologists a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible).60%60%
Patients who gave their nephrologists a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible).27%26%
Patients who gave their nephrologists a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible).13%14%

News Archive

Risk factors for head and neck cancer among WTC responders identified

A recent Rutgers study identified factors that may put people who responded to the 9/11 terrorist attacks at the World Trade Center at increased risk for cancers of the head and neck, such as oral cavity, oropharyngeal, and laryngeal cancers.

One-third of PsA patients not receiving adalimumab doses to achieve optimal clinical benefit

Data presented today at the European League Against Rheumatism Annual Congress showed that a significant number of patients with psoriatic arthritis (PsA) were not receiving doses of the tumour necrosis factor-alpha (TNFα) inhibitor adalimumab necessary to achieve optimal clinical benefit.

Zafgen presents safety, efficacy data from beloranib Phase 2 study at Obesity Week 2013

Zafgen, Inc., a leading biopharmaceutical company dedicated to addressing the unmet needs of severely obese patients, today announced final efficacy and safety data from its recently completed Phase 2 study of beloranib, a selective inhibitor of methionine aminopeptidase 2.

National veteran dataset will help dissect the relationship between mental illness and prostate cancer

There appears to be an unhealthy synergy between mental illness and prostate cancer, and researchers are working to dissect the relationship by first assembling the largest dataset ever of veterans with either condition or both.

Read more Medical News

› Verified 6 days ago

Dialysis Center Staff Performance Ratings

Experience MeasureProviderNational Avg.
Patients who reported that dialysis center staff always communicated well, kept patients comfortable and pain-free as possible.66%62%
Patients who reported that dialysis center staff usually communicated, kept patients comfortable and pain-free as possible.16%20%
Patients who reported that dialysis center staff sometimes or never communicated, kept patients comfortable and pain-free.18%18%
Patients who gave their dialysis facility staff a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible).57%62%
Patients who gave their dialysis facility staff a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible).31%26%
Patients who gave their dialysis facility staff a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible).12%12%

News Archive

Risk factors for head and neck cancer among WTC responders identified

A recent Rutgers study identified factors that may put people who responded to the 9/11 terrorist attacks at the World Trade Center at increased risk for cancers of the head and neck, such as oral cavity, oropharyngeal, and laryngeal cancers.

One-third of PsA patients not receiving adalimumab doses to achieve optimal clinical benefit

Data presented today at the European League Against Rheumatism Annual Congress showed that a significant number of patients with psoriatic arthritis (PsA) were not receiving doses of the tumour necrosis factor-alpha (TNFα) inhibitor adalimumab necessary to achieve optimal clinical benefit.

Zafgen presents safety, efficacy data from beloranib Phase 2 study at Obesity Week 2013

Zafgen, Inc., a leading biopharmaceutical company dedicated to addressing the unmet needs of severely obese patients, today announced final efficacy and safety data from its recently completed Phase 2 study of beloranib, a selective inhibitor of methionine aminopeptidase 2.

National veteran dataset will help dissect the relationship between mental illness and prostate cancer

There appears to be an unhealthy synergy between mental illness and prostate cancer, and researchers are working to dissect the relationship by first assembling the largest dataset ever of veterans with either condition or both.

Read more Medical News

› Verified 6 days ago

Overall Dialysis Center Performance Ratings

Experience MeasureProviderNational Avg.
Patients who reported that 'YES', their nephrologists and dialysis center staff provided them the information they needed to take care of them. 73%80%
Patients who reported that 'NO', their nephrologists and dialysis center staff does not provided them the information they needed to take care of them.27%20%
Patients who gave their dialysis center a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible).66%68%
Patients who gave their dialysis center a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible).27%20%
Patients who gave their dialysis center a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible).7%12%

News Archive

Risk factors for head and neck cancer among WTC responders identified

A recent Rutgers study identified factors that may put people who responded to the 9/11 terrorist attacks at the World Trade Center at increased risk for cancers of the head and neck, such as oral cavity, oropharyngeal, and laryngeal cancers.

One-third of PsA patients not receiving adalimumab doses to achieve optimal clinical benefit

Data presented today at the European League Against Rheumatism Annual Congress showed that a significant number of patients with psoriatic arthritis (PsA) were not receiving doses of the tumour necrosis factor-alpha (TNFα) inhibitor adalimumab necessary to achieve optimal clinical benefit.

Zafgen presents safety, efficacy data from beloranib Phase 2 study at Obesity Week 2013

Zafgen, Inc., a leading biopharmaceutical company dedicated to addressing the unmet needs of severely obese patients, today announced final efficacy and safety data from its recently completed Phase 2 study of beloranib, a selective inhibitor of methionine aminopeptidase 2.

National veteran dataset will help dissect the relationship between mental illness and prostate cancer

There appears to be an unhealthy synergy between mental illness and prostate cancer, and researchers are working to dissect the relationship by first assembling the largest dataset ever of veterans with either condition or both.

Read more Medical News

› Verified 6 days ago

Patient Distribution

Anemia Management

Dialysis patients with Hemoglobin data49
Medicare patients who had average hemoglobin (hgb) less than 10 g/dL14

News Archive

Risk factors for head and neck cancer among WTC responders identified

A recent Rutgers study identified factors that may put people who responded to the 9/11 terrorist attacks at the World Trade Center at increased risk for cancers of the head and neck, such as oral cavity, oropharyngeal, and laryngeal cancers.

One-third of PsA patients not receiving adalimumab doses to achieve optimal clinical benefit

Data presented today at the European League Against Rheumatism Annual Congress showed that a significant number of patients with psoriatic arthritis (PsA) were not receiving doses of the tumour necrosis factor-alpha (TNFα) inhibitor adalimumab necessary to achieve optimal clinical benefit.

Zafgen presents safety, efficacy data from beloranib Phase 2 study at Obesity Week 2013

Zafgen, Inc., a leading biopharmaceutical company dedicated to addressing the unmet needs of severely obese patients, today announced final efficacy and safety data from its recently completed Phase 2 study of beloranib, a selective inhibitor of methionine aminopeptidase 2.

National veteran dataset will help dissect the relationship between mental illness and prostate cancer

There appears to be an unhealthy synergy between mental illness and prostate cancer, and researchers are working to dissect the relationship by first assembling the largest dataset ever of veterans with either condition or both.

Read more Medical News

› Verified 6 days ago

Dialysis Adequacy

Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.

  • Hemodialysis
    Adult patients getting regular hemodialysis at the center117
    Adult patient months included in Kt/V greater than or equal to 1.2942
    Percentage of adult patients getting regular hemodialysis at the center97
    Percentage of pediatric patients getting regular hemodialysis at the center

    News Archive

    Risk factors for head and neck cancer among WTC responders identified

    A recent Rutgers study identified factors that may put people who responded to the 9/11 terrorist attacks at the World Trade Center at increased risk for cancers of the head and neck, such as oral cavity, oropharyngeal, and laryngeal cancers.

    One-third of PsA patients not receiving adalimumab doses to achieve optimal clinical benefit

    Data presented today at the European League Against Rheumatism Annual Congress showed that a significant number of patients with psoriatic arthritis (PsA) were not receiving doses of the tumour necrosis factor-alpha (TNFα) inhibitor adalimumab necessary to achieve optimal clinical benefit.

    Zafgen presents safety, efficacy data from beloranib Phase 2 study at Obesity Week 2013

    Zafgen, Inc., a leading biopharmaceutical company dedicated to addressing the unmet needs of severely obese patients, today announced final efficacy and safety data from its recently completed Phase 2 study of beloranib, a selective inhibitor of methionine aminopeptidase 2.

    National veteran dataset will help dissect the relationship between mental illness and prostate cancer

    There appears to be an unhealthy synergy between mental illness and prostate cancer, and researchers are working to dissect the relationship by first assembling the largest dataset ever of veterans with either condition or both.

    Read more Medical News

    › Verified 6 days ago

Mineral and Bone Disorder

An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Fmc-Inglewood with elevated calcium levels.

Patients with hypercalcemia123
Hypercalcemia patient months1011
Hypercalcemia patients with serumcalcium greater than 10.2 mg1
Patients with Serumphosphor120
Patients with Serumphosphor less than 3.5 mg/dL13
Patients with Serumphosphor from 3.5 to 4.5 mg/dL28
Patients with Serumphosphor from 4.6 to 5.5 mg/dL28
Patients with Serumphosphor from 5.6 to 7 mg/dL19
Patients with Serumphosphor greater than 7 mg/dL12

News Archive

Risk factors for head and neck cancer among WTC responders identified

A recent Rutgers study identified factors that may put people who responded to the 9/11 terrorist attacks at the World Trade Center at increased risk for cancers of the head and neck, such as oral cavity, oropharyngeal, and laryngeal cancers.

One-third of PsA patients not receiving adalimumab doses to achieve optimal clinical benefit

Data presented today at the European League Against Rheumatism Annual Congress showed that a significant number of patients with psoriatic arthritis (PsA) were not receiving doses of the tumour necrosis factor-alpha (TNFα) inhibitor adalimumab necessary to achieve optimal clinical benefit.

Zafgen presents safety, efficacy data from beloranib Phase 2 study at Obesity Week 2013

Zafgen, Inc., a leading biopharmaceutical company dedicated to addressing the unmet needs of severely obese patients, today announced final efficacy and safety data from its recently completed Phase 2 study of beloranib, a selective inhibitor of methionine aminopeptidase 2.

National veteran dataset will help dissect the relationship between mental illness and prostate cancer

There appears to be an unhealthy synergy between mental illness and prostate cancer, and researchers are working to dissect the relationship by first assembling the largest dataset ever of veterans with either condition or both.

Read more Medical News

› Verified 6 days ago

Vascular Access

The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.

Patients included in arterial venous fistula and catheter summaries 106
Patient months included in arterial venous fistula and catheter summaries 671
Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment52
Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer12

News Archive

Risk factors for head and neck cancer among WTC responders identified

A recent Rutgers study identified factors that may put people who responded to the 9/11 terrorist attacks at the World Trade Center at increased risk for cancers of the head and neck, such as oral cavity, oropharyngeal, and laryngeal cancers.

One-third of PsA patients not receiving adalimumab doses to achieve optimal clinical benefit

Data presented today at the European League Against Rheumatism Annual Congress showed that a significant number of patients with psoriatic arthritis (PsA) were not receiving doses of the tumour necrosis factor-alpha (TNFα) inhibitor adalimumab necessary to achieve optimal clinical benefit.

Zafgen presents safety, efficacy data from beloranib Phase 2 study at Obesity Week 2013

Zafgen, Inc., a leading biopharmaceutical company dedicated to addressing the unmet needs of severely obese patients, today announced final efficacy and safety data from its recently completed Phase 2 study of beloranib, a selective inhibitor of methionine aminopeptidase 2.

National veteran dataset will help dissect the relationship between mental illness and prostate cancer

There appears to be an unhealthy synergy between mental illness and prostate cancer, and researchers are working to dissect the relationship by first assembling the largest dataset ever of veterans with either condition or both.

Read more Medical News

› Verified 6 days ago

Hospitalization Rate

The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.

Standard Hospitalization Summary Ratio(SHR) YearJanuary, 2016 - December, 2016
Patients in facility's Hospitalization Summary84
Hospitalization Rate in facility255.8 (As Expected)
Hospitalization Rate: Upper Confidence Limit390.6
Hospitalization Rate: Lower Confidence Limit171.4

News Archive

Risk factors for head and neck cancer among WTC responders identified

A recent Rutgers study identified factors that may put people who responded to the 9/11 terrorist attacks at the World Trade Center at increased risk for cancers of the head and neck, such as oral cavity, oropharyngeal, and laryngeal cancers.

One-third of PsA patients not receiving adalimumab doses to achieve optimal clinical benefit

Data presented today at the European League Against Rheumatism Annual Congress showed that a significant number of patients with psoriatic arthritis (PsA) were not receiving doses of the tumour necrosis factor-alpha (TNFα) inhibitor adalimumab necessary to achieve optimal clinical benefit.

Zafgen presents safety, efficacy data from beloranib Phase 2 study at Obesity Week 2013

Zafgen, Inc., a leading biopharmaceutical company dedicated to addressing the unmet needs of severely obese patients, today announced final efficacy and safety data from its recently completed Phase 2 study of beloranib, a selective inhibitor of methionine aminopeptidase 2.

National veteran dataset will help dissect the relationship between mental illness and prostate cancer

There appears to be an unhealthy synergy between mental illness and prostate cancer, and researchers are working to dissect the relationship by first assembling the largest dataset ever of veterans with either condition or both.

Read more Medical News

› Verified 6 days ago

Readmission Rate

The rate of readmission show you whether patients who were being treated regularly at Fmc-Inglewood were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.

Standard Readmission Summary Ratio(SRR) YearJanuary, 2016 - December, 2016
Readmission Rate in facility40.5 (As Expected)
Readmission Rate: Upper Confidence Limit51.8
Readmission Rate: Lower Confidence Limit29.5

News Archive

Risk factors for head and neck cancer among WTC responders identified

A recent Rutgers study identified factors that may put people who responded to the 9/11 terrorist attacks at the World Trade Center at increased risk for cancers of the head and neck, such as oral cavity, oropharyngeal, and laryngeal cancers.

One-third of PsA patients not receiving adalimumab doses to achieve optimal clinical benefit

Data presented today at the European League Against Rheumatism Annual Congress showed that a significant number of patients with psoriatic arthritis (PsA) were not receiving doses of the tumour necrosis factor-alpha (TNFα) inhibitor adalimumab necessary to achieve optimal clinical benefit.

Zafgen presents safety, efficacy data from beloranib Phase 2 study at Obesity Week 2013

Zafgen, Inc., a leading biopharmaceutical company dedicated to addressing the unmet needs of severely obese patients, today announced final efficacy and safety data from its recently completed Phase 2 study of beloranib, a selective inhibitor of methionine aminopeptidase 2.

National veteran dataset will help dissect the relationship between mental illness and prostate cancer

There appears to be an unhealthy synergy between mental illness and prostate cancer, and researchers are working to dissect the relationship by first assembling the largest dataset ever of veterans with either condition or both.

Read more Medical News

› Verified 6 days ago

Infection Rate

Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at Fmc-Inglewood get infections in their blood each year compared to the number of infections expected for the center based on the national average.

Standard Infection Summary Ratio(SIR) YearJanuary, 2016 - December, 2016
Infection Rate in facility.54 (As Expected)
SIR: Upper Confidence Limit1.29
SIR: Lower Confidence Limit.17

News Archive

Risk factors for head and neck cancer among WTC responders identified

A recent Rutgers study identified factors that may put people who responded to the 9/11 terrorist attacks at the World Trade Center at increased risk for cancers of the head and neck, such as oral cavity, oropharyngeal, and laryngeal cancers.

One-third of PsA patients not receiving adalimumab doses to achieve optimal clinical benefit

Data presented today at the European League Against Rheumatism Annual Congress showed that a significant number of patients with psoriatic arthritis (PsA) were not receiving doses of the tumour necrosis factor-alpha (TNFα) inhibitor adalimumab necessary to achieve optimal clinical benefit.

Zafgen presents safety, efficacy data from beloranib Phase 2 study at Obesity Week 2013

Zafgen, Inc., a leading biopharmaceutical company dedicated to addressing the unmet needs of severely obese patients, today announced final efficacy and safety data from its recently completed Phase 2 study of beloranib, a selective inhibitor of methionine aminopeptidase 2.

National veteran dataset will help dissect the relationship between mental illness and prostate cancer

There appears to be an unhealthy synergy between mental illness and prostate cancer, and researchers are working to dissect the relationship by first assembling the largest dataset ever of veterans with either condition or both.

Read more Medical News

› Verified 6 days ago

Transfusion Summary

Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether Fmc-Inglewood's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.

Standard Transfusion Summary Ratio (STrR) Year January, 2016 - December, 2016
Patients in facility's Transfusion Summary 78
Transfusion Rate in facility40.5 (As Expected)
Transfusion Rate: Upper Confidence Limit91.1
Transfusion Rate: Lower Confidence Limit19.9

News Archive

Risk factors for head and neck cancer among WTC responders identified

A recent Rutgers study identified factors that may put people who responded to the 9/11 terrorist attacks at the World Trade Center at increased risk for cancers of the head and neck, such as oral cavity, oropharyngeal, and laryngeal cancers.

One-third of PsA patients not receiving adalimumab doses to achieve optimal clinical benefit

Data presented today at the European League Against Rheumatism Annual Congress showed that a significant number of patients with psoriatic arthritis (PsA) were not receiving doses of the tumour necrosis factor-alpha (TNFα) inhibitor adalimumab necessary to achieve optimal clinical benefit.

Zafgen presents safety, efficacy data from beloranib Phase 2 study at Obesity Week 2013

Zafgen, Inc., a leading biopharmaceutical company dedicated to addressing the unmet needs of severely obese patients, today announced final efficacy and safety data from its recently completed Phase 2 study of beloranib, a selective inhibitor of methionine aminopeptidase 2.

National veteran dataset will help dissect the relationship between mental illness and prostate cancer

There appears to be an unhealthy synergy between mental illness and prostate cancer, and researchers are working to dissect the relationship by first assembling the largest dataset ever of veterans with either condition or both.

Read more Medical News

› Verified 6 days ago

Survival Summary

The rate of mortality show you whether patients who were being treated regularly at Fmc-Inglewood lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.

Standard Survival Summary Ratio(SIR) YearJanuary, 2013 - December, 2016
Patients in facility's Survival Summary459
Mortality Rate in facility17.2 (As Expected)
Mortality Rate: Upper Confidence Limit22.9
Mortality Rate: Lower Confidence Limit12.7

News Archive

Risk factors for head and neck cancer among WTC responders identified

A recent Rutgers study identified factors that may put people who responded to the 9/11 terrorist attacks at the World Trade Center at increased risk for cancers of the head and neck, such as oral cavity, oropharyngeal, and laryngeal cancers.

One-third of PsA patients not receiving adalimumab doses to achieve optimal clinical benefit

Data presented today at the European League Against Rheumatism Annual Congress showed that a significant number of patients with psoriatic arthritis (PsA) were not receiving doses of the tumour necrosis factor-alpha (TNFα) inhibitor adalimumab necessary to achieve optimal clinical benefit.

Zafgen presents safety, efficacy data from beloranib Phase 2 study at Obesity Week 2013

Zafgen, Inc., a leading biopharmaceutical company dedicated to addressing the unmet needs of severely obese patients, today announced final efficacy and safety data from its recently completed Phase 2 study of beloranib, a selective inhibitor of methionine aminopeptidase 2.

National veteran dataset will help dissect the relationship between mental illness and prostate cancer

There appears to be an unhealthy synergy between mental illness and prostate cancer, and researchers are working to dissect the relationship by first assembling the largest dataset ever of veterans with either condition or both.

Read more Medical News

› Verified 6 days ago


Dialysis Facility in Inglewood, CA

Davita-Inglewood Dialysis
Location: 125 E. Arbor Vitae, Inglewood, California, 90301
Phone: (310) 677-6114
Fmc-Rai-Centinela-Inglewood
Location: 1416 Centinela Avenue, Inglewood, California, 90302
Phone: (310) 673-6865
Davita-Imperial Dialysis
Location: 2738 W. Imperial Highway, Inglewood, California, 90303
Phone: (323) 779-5399
Davita-Airport Sunrise Dialysis Center
Location: 11300 Hawthorne Blvd, Inglewood, California, 90304
Phone: (310) 680-0601
Fmc-Inglewood
Location: 336 E. Hillcrest Avenue, Suite 100, Inglewood, California, 90301
Phone: (310) 673-3656

News Archive

Risk factors for head and neck cancer among WTC responders identified

A recent Rutgers study identified factors that may put people who responded to the 9/11 terrorist attacks at the World Trade Center at increased risk for cancers of the head and neck, such as oral cavity, oropharyngeal, and laryngeal cancers.

One-third of PsA patients not receiving adalimumab doses to achieve optimal clinical benefit

Data presented today at the European League Against Rheumatism Annual Congress showed that a significant number of patients with psoriatic arthritis (PsA) were not receiving doses of the tumour necrosis factor-alpha (TNFα) inhibitor adalimumab necessary to achieve optimal clinical benefit.

Zafgen presents safety, efficacy data from beloranib Phase 2 study at Obesity Week 2013

Zafgen, Inc., a leading biopharmaceutical company dedicated to addressing the unmet needs of severely obese patients, today announced final efficacy and safety data from its recently completed Phase 2 study of beloranib, a selective inhibitor of methionine aminopeptidase 2.

National veteran dataset will help dissect the relationship between mental illness and prostate cancer

There appears to be an unhealthy synergy between mental illness and prostate cancer, and researchers are working to dissect the relationship by first assembling the largest dataset ever of veterans with either condition or both.

Read more Medical News

› Verified 6 days ago


Find & Compare Providers Near You: Find and compare doctors, nursing homes, hospitals, and other health care providers in your area that accept Medicare. Get information like: Find a doctor or clinician that accepts Medicare near you.

Doctors and clinicians: Doctors and clinicians include doctors, clinicians and groups who are qualified to practice in many specialties. Each specialty focuses on certain parts of the body, periods of life, conditions, or primary care. The doctors, clinicians, and groups listed here typically work in an office or clinic setting. Also those who currently accept Medicare are included.

Hospitals: Find information about Medicare-certified hospitals and long-term care hospitals in your area, including Veterans Administration medical centers and military hospitals, across the country. Long-term care hospitals serve critically ill and medically complex patients who require extended hospital care.

Data provided: Information on www.medicareusa.org is built using open data sources published by Centers for Medicare & Medicaid Services (CMS) under Freedom of Information Act (FOIA).

© 2024 MedicareUsa. All rights reserved. Maintained by the Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services.